UBCS039
Based on 17 publication(s) in Google Scholar
UBCS039 is the first synthetic, specific Sirtuin 6 (SIRT6) activator, inducing autophagy in human tumor cells, with an EC50 of 38 μM.
For research use only. We do not sell to patients.
- Purity: 98.88%
- CAS No.: 358721-70-7
- Formula: C16H13N3
- Molecular Weight:247.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Glutamine Metabolism Compound Library
HY-L064
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) UBCS039
More- J Hazard Mater. 2024 Jul 8:476:135159. [Abstract]
- Acta Pharmacol Sin. 2025 Feb;46(2):416-429. [Abstract]
- Free Radic Biol Med. 2025 Nov:239:432-448. [Abstract]
- Free Radic Biol Med. 2025 Apr 15:S0891-5849(25)00231-X. [Abstract]
- J Med Chem. 2020 Sep 24;63(18):10474-10495. [Abstract]
- Cell Biosci. 2021 Dec 14;11(1):210. [Abstract]
- Biochem Pharmacol. 2025 Oct 29;243(Pt 1):117496. [Abstract]
- PLoS Pathog. 2023 Apr 6;19(4):e1011324. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 2):115878. [Abstract]
- Toxicology. 2026 Mar:521:154404. [Abstract]
- Mol Neurobiol. 2022 Jan;59(1):429-444. [Abstract]
- FASEB J. 2025 May 15;39(9):e70579. [Abstract]
- Cell Signal. 2025 Jul:131:111757. [Abstract]
- Neurobiol Stress. 2026 Mar 21:42:100804. [Abstract]
- Cytotherapy. 2022 Feb;24(2):149-160. [Abstract]
- Ren Fail. 2024 Dec;46(2):2410396. [Abstract]
- Research Square Print. 2023 Jan 30th.
Customer Validation & Images
-
IF
-
WB
-
WB
-
RT-PCR
Biological Activity
|
SIRT6 38 μM (EC50) |
UBCS039 (75 μM, 48 or 72 hours) induces deacetylation of SIRT6-targeted histone H3 sites in human cancer cells[2].
UBCS039 leads to autophagosome accumulation in human cancer cells[2].
UBCS039 induces autophagy via AMP-activated protein kinase (AMPK) signaling pathway activation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human H1299 cells.
-
Concentration:75 μM.
-
Incubation Time:48 and 72 hours.
-
Result:Induced deacetylation of SIRT6-targeted histone H3 sites in human H1299 cells.
-
Cell Line:Human H1299 cells.
-
Concentration:75 μM.
-
Incubation Time:48 and 72 hours.
-
Result:Induced deacetylation of SIRT6-targeted histone H3 sites in human H1299 cells.
-
Cell Line:Human H1299 cells.
-
Concentration:100 μM.
-
Incubation Time:48 and 72 hours.
-
Result:Led to a strong decrease of cell proliferation in a dose-dependent manner when compared with control or DMSO-treated cells, starting from day 3 of growth (48 h after treatment) in both H1299 and HeLa cell lines.
Chemical Information
-
CAS No. 358721-70-7
-
Appearance Solid
-
Molecular Weight 247.29
-
Formula C16H13N3
-
Color Light yellow to yellow
-
SMILES
N12C(C(C3=CC=CN=C3)NC4=C2C=CC=C4)=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
J Hazard Mater
Adolescent co-exposure to environmental cadmium and high-fat diet induces cognitive decline via Larp7 m6A-mediated SIRT6 inhibition. [Abstract]2024 Jul 8:476:135159. PMID: 39002485 -
Acta Pharmacol Sin
Oral administration of astilbin mitigates acetaminophen-induced acute liver injury in mice by modulating the gut microbiota. [Abstract]2025 Feb;46(2):416-429. PMID: 39313515
UBCS039 purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Feb;46(2):416-429. [Abstract]
Representative micrographs of ROS levels in primary hepatocytes with or without UBCS039 (100 μM) pretreatment.
UBCS039 purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Feb;46(2):416-429. [Abstract]
Protein expression of p-Nrf2, HO1, and NQO1 in primary hepatocytes pretreated with PBS or UBCS039 (100 μM) in the presence or absence of HT.
-
Free Radic Biol Med
Hyperactivation of the m6A demethylase FTO to down-regulate SLC7A11/xCT-mediated redox homeostasis and epigenetic remodeling in facial infiltrating lipomatosis. [Abstract]2025 Nov:239:432-448. PMID: 40769313 -
Free Radic Biol Med
Nicotinamide mononucleotide mitigates hyperoxia-aggravated septic lung injury via the GPx4-mediated anti-ferroptosis signaling pathway in alveolar epithelial cells. [Abstract]2025 Apr 15:S0891-5849(25)00231-X. PMID: 40246251 -
J Med Chem
Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity. [Abstract]2020 Sep 24;63(18):10474-10495. PMID: 32787077 -
Cell Biosci
SIRT6 inhibition delays peripheral nerve recovery by suppressing migration, phagocytosis and M2-polarization of macrophages. [Abstract]2021 Dec 14;11(1):210. PMID: 34906231 -
Biochem Pharmacol
2025 Oct 29;243(Pt 1):117496. PMID: 41173054 -
PLoS Pathog
Immune evasion strategy involving propionylation by the KSHV interferon regulatory factor 1 (vIRF1). [Abstract]2023 Apr 6;19(4):e1011324. PMID: 37023208
UBCS039 purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2023 Apr 6;19(4):e1011324. [Abstract]
UBCS039 (80 μM; 24 h) enhances the expression of SIRT6 in iSLK-RGB and THP-1cells.
UBCS039 purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2023 Apr 6;19(4):e1011324. [Abstract]
IFN-β mRNA levels were detected by RT-qPCR treated with UBCS039 (80 μM).
-
Int Immunopharmacol
Sirtuin 6 activator UBCS039 ameliorates hepatic lipogenesis through liver X receptor deacetylation. [Abstract]2026 Jan 1;168(Pt 2):115878. PMID: 41265217 -
Toxicology
PM2.5 induces cardiac defects by triggering endoplasmic reticulum stress mediated through the impairment of SIRT6 deacetylase activity. [Abstract]2026 Mar:521:154404. PMID: 41544926 -
Mol Neurobiol
SIRT6 Negatively Regulates Schwann Cells Dedifferentiation via Targeting c-Jun During Wallerian Degeneration After Peripheral Nerve Injury. [Abstract]2022 Jan;59(1):429-444. PMID: 34708329 -
FASEB J
PRMT1 Upregulates SIRT6 by Enhancing Arginine Methylation of E2F7 to Inhibit Vascular Smooth Muscle Cell Senescence in Aortic Dissection. [Abstract]2025 May 15;39(9):e70579. PMID: 40298071 -
Cell Signal
SIRT6 mitigates acute kidney injury by enhancing lipid metabolism and reducing tubular epithelial cell apoptosis via suppression of the ACMSD signaling pathway. [Abstract]2025 Jul:131:111757. PMID: 40120964 -
Neurobiol Stress
Microglial SIRT6 confers protection against neuroinflammation-associated depression through NRF2-HO1 signaling. [Abstract]2026 Mar 21:42:100804. PMID: 41938092 -
Cytotherapy
Sirtuin 6 regulates macrophage polarization to alleviate sepsis-induced acute respiratory distress syndrome via dual mechanisms dependent on and independent of autophagy. [Abstract]2022 Feb;24(2):149-160. PMID: 34920961 -
Ren Fail
Sirt6 ameliorates high glucose-induced podocyte cytoskeleton remodeling via the PI3K/AKT signaling pathway. [Abstract]2024 Dec;46(2):2410396. PMID: 39378103 -
Solvent & Solubility
DMSO : 100 mg/mL (404.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0438 mL | 20.2192 mL | 40.4384 mL | 101.0959 mL |
| 5 mM | 0.8088 mL | 4.0438 mL | 8.0877 mL | 20.2192 mL | |
| 10 mM | 0.4044 mL | 2.0219 mL | 4.0438 mL | 10.1096 mL | |
| 15 mM | 0.2696 mL | 1.3479 mL | 2.6959 mL | 6.7397 mL | |
| 20 mM | 0.2022 mL | 1.0110 mL | 2.0219 mL | 5.0548 mL | |
| 25 mM | 0.1618 mL | 0.8088 mL | 1.6175 mL | 4.0438 mL | |
| 30 mM | 0.1348 mL | 0.6740 mL | 1.3479 mL | 3.3699 mL | |
| 40 mM | 0.1011 mL | 0.5055 mL | 1.0110 mL | 2.5274 mL | |
| 50 mM | 0.0809 mL | 0.4044 mL | 0.8088 mL | 2.0219 mL | |
| 60 mM | 0.0674 mL | 0.3370 mL | 0.6740 mL | 1.6849 mL | |
| 80 mM | 0.0505 mL | 0.2527 mL | 0.5055 mL | 1.2637 mL | |
| 100 mM | 0.0404 mL | 0.2022 mL | 0.4044 mL | 1.0110 mL |
UBCS039 Related Classifications
HY-115453 Related Classifications
Powered by Bioz